Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 5/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 4/20 | 0.46 |
| ▸ | HTR2C | P28335 | 4/20 | 0.46 |
| ▸ | HTR2B | P41595 | 3/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5636655 | 0.79 | HTR2A (0.64) | KMOCHRM1HTR2AHTR2CHTR2B | |
| SCHEMBL4946400 | 0.79 | HTR2A (0.64) | KMOCHRM1HTR2AHTR2CHTR2B | |
| SCHEMBL6203362 | 0.76 | KMO (0.42) | KMOCHRM2CHRM1HTR2AHTR2C | |
| SCHEMBL5782920 | 0.75 | CHRM2 (0.46) | KMOCHRM2CHRM1HTR2AHTR2C | |
| SCHEMBL5782917 | 0.75 | CHRM2 (0.46) | KMOCHRM2CHRM1HTR2AHTR2C | |
| SCHEMBL5055858 | 0.75 | MCHR1 (0.47) | KMOHTR2AHTR2CHTR2BMAOA | |
| SCHEMBL4779482 | 0.75 | MCHR1 (0.47) | KMOHTR2AHTR2CHTR2BMAOA | |
| SCHEMBL6359649 | 0.71 | HTR2A (0.54) | KMOCHRM2CHRM1HTR2AHTR2C | |
| SCHEMBL3545732 | 0.67 | HTR2A (0.51) | KMOHTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL5783787 | 0.67 | HTR2A (0.51) | KMOHTR2AHTR2CHTR2BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392292-B1 | PYRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | ALCON INC (CH) | 2006-03-01 | — | — | EP | disclosed |
| US-6881749-B2 | Pyranoindazoles and their use for the treatment of glaucoma | ALCON, INC. (CH) | 2005-04-19 | — | — | US | disclosed |
| US-20040106609-A1 | Pyranoindazoles and their use for the treatment of glaucoma | NOVARTIS AG (CH) | 2004-06-03 | — | — | US | disclosed |
| US-6696476-B2 | SUCH AS 1-(2-AMINOPROPYL)-1,7,8,9-TETRAHYDRO-PYRANO(2,3-G)-INDAZOL-8-OL; LOWERING AND CONTROLLING INTRAOCULAR PRESSURE | ALCON, INC. (CH) | 2004-02-24 | — | — | US | disclosed |
| US-20030171418-A1 | Reducing or controlling eye pressure | NOVARTIS AG (CH) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106609-A1 | Pyranoindazoles and their use for the treatment of glaucoma | PDE3A, CYP11B2, PDE3B | KMO 1212/4885CHRM2 680/4885CHRM1 1481/4885 |
| US-20030171418-A1 | Reducing or controlling eye pressure | PDE3A, PDE3B, QDPR | KMO 1345/4885CHRM2 365/4885CHRM1 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.